Healthcare

Innovations in Liquid Biopsy Techniques for Cancer Management Updated Research Available

Liquid Biopsy Technologies Likely to Lead the Transformation of Cancer Profiling and Personalized Treatment Strategies

INDUSTRY
Healthcare

RELEASE DATE
01-Aug-2017
REGION
Global
DELIVERABLE TYPE
Technology Research

RESEARCH CODE
D7CC-01-00-00-00
SKU
HC02857-GL-TR_20493
Yes
SHARE

Innovations in Liquid Biopsy Techniques for Cancer Management
Published on: 01-Aug-2017 | SKU: HC02857-GL-TR_20493

Need more details?

$4,950.00

$3,712.50 save 25 %

DownloadLink
Need more details?

This research service encompasses a comprehensive analysis of minimally-invasive and non-invasive biopsy platforms that enable enhanced tumor profiling, treatment monitoring and precision oncology applications. This service primarily focuses on the use of circulating tumor DNA (ctDNA) circulating tumor cells (CTCs) and extracellular vesicles (EVs), derived from bio-fluids such as blood and urine, for molecular analysis across research and healthcare settings. This study also evaluates the technology, clinical, patent, and application landscapes prevalent across liquid biopsy settings, while providing valuable insights across its global technological impact and future perspectives.

1.1 Research Scope

1.2 Research Methodology

1.2 Research Methodology (Continued)

1.3 Key Findings

2.1 Overview of Key Liquid Biopsy (LB) Markers

2.2 Key Liquid Biopsy Markers Comprise Circulating Tumor DNA (ctDNA), Circulating Tumor Cells (CTCs) and Extracellular Vesicles (EVs)

3.1 Next-Generation Sequencing Platforms Likely to Fuel ctDNA Analysis

3.2 Overview of PCR-Based Technologies for ctDNA Analysis

3.3 Next-Generation Sequencing Tools for ctDNA Assessment

3.4 Emerging ctDNA Technologies Likely to Enable Comprehensive genome Profiling

3.5 ctDNA Leads Profiling and Therapy Monitoring Applications in Clinical Trial Studies

3.6 China Leads the Global Patent Landscape for ctDNA-based Technologies

3.7 Research Funding in US for ctDNA-based Projects Exceed $50M in 2015-2016 Period

3.8 ctDNA Biomarkers Studies Likely to Accelerate Disease and Treatment Profiling Applications

3.9 Leveraging Epigenetic Tools across Cancer Diagnostics

3.10 Enabling Personalized Management of Cancer

4.1 Circulating Tumor Cells Enable Comprehensive Analysis of Cancer

4.2 Cellular Analytics for CTCs Enable Prognostic Insights for Cancer

4.3 Technologies Facilitating Molecular Analysis of CTCs Likely to Transform Cancer Management

4.4 Emerging Use of Microfluidic and Imaging Technologies Enhance CTC Analysis

4.5 China Leads the Global Patent Landscape for CTCs

4.6 NIH funding for CTC-based Projects Exceeded $150 million during 2015-2016

4.7 CTCs Likely to Lead Disease Profiling, Treatment Profiling and Prognostic Applications across Several Cancers

4.8 Combining ctDNA and CTC Analyses for Liquid Biopsy Assays

4.9 US FDA Approved CTC Assay

5.1 Exosomes Likely to Garner Growing Attention across Cancer Liquid Biopsy Applications

5.2 Affinity Capture and Microfluidics techniques Likely to Enhance Exosome Isolation and Detection in the Near Future

5.3 Advances across Proteomic and Nucleic Acid Assay Techniques Likely to Enhance Exosome Markers Detection

5.4 North America Leads the Global Patent Landscape for Extracellular Vesicle-based Technologies

5.5 US Research Funding for EV-based Technologies Exceeds $250 Million during 2015-2016

5.6 Exosomal Markers Likely to Lead Disease Profiling and Treatment Monitoring Applications

5.7 Exosome-based Liquid Biopsy Assays for Precision Oncology

5.8 Novel Platforms for Enhanced Isolation of EVs

6.1 Summary of Key Technology Drivers

6.2 Technology Advancements and Rising Preference for Minimally Invasive Methods Likely to Fuel Liquid Biopsy Platforms

6.3 Summary of Key Technology Challenges

6.4 Enhancing Assay Accuracy and Clinical Utility of Biomarkers Constitute Key Challenges across Liquid Biopsy Tests

6.5 Liquid Biopsy Platforms Likely to Transform Disease Profiling and Precision Medicine Applications

7.1 Growth Opportunity 1: ctDNA

7.2 Growth Opportunity 2: CTCs

7.3 Growth Opportunity 3: EVs

7.4 Strategic Imperatives for Success and Growth

8.1 Key Contacts

8.1 Key Contacts (continued)

Legal Disclaimer

9.1 The Frost & Sullivan Story

9.2 Value Proposition: Future of Your Company & Career

9.3 Global Perspective

9.4 Industry Convergence

9.5 360º Research Perspective

9.6 Implementation Excellence

9.7 Our Blue Ocean Strategy


Have questions about this research or need deeper insights?
Speak directly with our analytics experts for tailored recommendations.

Recent related Healthcare research

16 Nov 2026   |   North America   |   Frost Radar

Frost Radar™: Healthcare Data Interoperability Platforms and Integration Engines in North America, 2026

This Frost Radar™ analyzes the healthcare data platform and integration engine vendors that enable healthcare organization to improve the exchange, utilization, contextualization, and management of clinical, operational, financial, and administrative data. Data issues, AI adoption, and solution gove...

03 Nov 2026   |   North America   |   Market Research

Enterprise Imaging Market, United States, 2025–2030

Enterprise imaging is no longer a technology upgrade. It is becoming the operating model for imaging across the provider organization, and the next investment cycle will decide which vendors lead it. This study gives vendors, ecosystem partners, and provider leaders a 360-degree view of that shift, ...

02 Nov 2026   |   Global   |   Market Research

Continuous Glucose Monitoring Market, Global, 2026

The global continuous glucose monitoring (CGM) market is undergoing a fundamental transformation as the technology evolves from a prescription-led glucose monitoring device into an AI-connected metabolic intelligence ecosystem. Market expansion is increasingly driven by the emergence of over-the-cou...

28 Oct 2026   |   Global   |   Frost Radar

Frost Radar™: Health Monitoring Wearable Solutions, 2026

The health monitoring wearables industry is undergoing a profound transformation as competitive advantage shifts from device hardware to integrated digital health ecosystems. Market leaders are differentiating through clinically validated health insights, longitudinal data platforms, AI-enabled anal...

26 Oct 2026   |   Global   |   Technology Research

Game-Changing Innovations Transforming Cardiovascular Care

The study analyzes game-changing technologies transforming cardiovascular care across diagnosis, image-guided intervention, functional assessment, clinical workflow, and longitudinal patient monitoring. The analysis covers five segments: diagnostic imaging and AI-enabled cardiac assessment; interve...

 

Purchase includes:
  • Report download
  • Growth Dialog™ with our experts

Growth Dialog™

A tailored session with you where we identify the:
  • Strategic Imperatives
  • Growth Opportunities
  • Best Practices
  • Companies to Action

Impacting your company's future growth potential.